AK Global Asset Management LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,455 shares of the company’s stock, valued at approximately $1,090,000. Tempus AI accounts for approximately 1.0% of AK Global Asset Management LLC’s holdings, making the stock its 19th biggest position.
Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Capital LLC raised its position in shares of Tempus AI by 26.9% during the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after acquiring an additional 17,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Tempus AI by 1,459.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI in the third quarter valued at about $1,695,000. Vanguard Group Inc. grew its stake in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after acquiring an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC lifted its holdings in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.
Insider Buying and Selling at Tempus AI
In other news, CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Ryan M. Bartolucci sold 2,902 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the transaction, the chief accounting officer owned 41,159 shares of the company’s stock, valued at $2,430,438.95. This trade represents a 6.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 563,841 shares of company stock worth $32,258,311. Company insiders own 26.27% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on TEM
Tempus AI Price Performance
Shares of NASDAQ TEM opened at $46.81 on Wednesday. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The stock’s 50 day moving average price is $52.17 and its 200-day moving average price is $67.58. The company has a market capitalization of $8.37 billion, a PE ratio of -33.20 and a beta of 4.90.
Tempus AI Company Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
